PAHC — Phibro Animal Health Corporation stock price, charts and financials

QT47Phibro Animal Health Corporation

Phibro Animal Health Corporation (NASDAQ: PAHC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
34.45
-0.85-2.41%
PAHCQT47Phibro Animal Health Corporation·NASDAQ
34.45-2.41%
News
Down 2.4% — Phibro Animal Health Corporation $PAHC Shares Acquired by Engineers Gate Manager LP (defenseworld.net).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E14.12EPS (ttm)2.44Insider Own-Shs Outstand40.54MPerf Week-5.82%
Market Cap1.40BForward P/E8.95EPS next Y3.85Insider Trans-0.25%Shs Float40.24MPerf Month-0.58%
Enterprise Value2.09BPEG1.26EPS next Q0.77Inst Own-Short Float3.00%Perf Quarter11.71%
Income100.00MP/S0.92EPS this Y43.50%Inst Trans-Short Ratio4.57Perf Half Y-34.04%
Sales1.52BP/B3.63EPS next Y9.98%ROA6.64%Short Interest1.21MPerf YTD-7.79%
Book/sh9.50P/C17.03EPS next 5Y11.17%ROE28.67%52W High60.08 -42.66%Perf Year-11.69%
Cash/sh2.02P/FCF146.36EPS past 3/5Y44.42% 12.73%ROIC11.81%52W Low28.25 21.95%Perf 3Y171.69%
Dividend Est.0.48 (1.39%)EV/EBITDA8.83Sales past 3/5Y15.78% 12.75%Gross Margin33.71%Volatility3.69% 4.04%Perf 5Y47.60%
Dividend TTM0.48 (1.39%)EV/Sales1.38EPS Y/Y TTM105.04%Oper. Margin13.07%ATR (14)1.43Perf 10Y30.69%
Dividend Ex-DateSep 02, 2026Quick Ratio1.27Sales Y/Y TTM17.21%Profit Margin6.57%RSI (14)40.30Recom2.86
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio2.96EPS Q/Q34.92%SMA20-5.97%Beta0.43Target Price28.00
Payout19.52%Debt/Eq2.02Sales Q/Q4.75%SMA50-2.66%Rel Volume0.86Prev Close35.30
Employees2,605LT Debt/Eq1.96EarningsNov 04SMA200-17.18%Avg Volume247.75KPrice34.45
IPO DateApr 11, 2014Option/ShortYes / YesEPS/Sales Surpr.19.25% 4.07%Net Debt/EBITDA3.08Volume212,033Change-2.41%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-06-26ReiteratedMorgan StanleyEqual Weight$45$49
Aug-28-25ReiteratedMorgan StanleyEqual Weight$26$34
Jul-07-25UpgradeJP MorganNeutralOverweight
Jun-25-25ReiteratedMorgan StanleyEqual Weight$20$26
Apr-15-25ReiteratedMorgan StanleyEqual Weight$27$20
Dec-21-22ReiteratedRoth CapitalBuy$18
Sep-16-22ReiteratedBarclaysUnderweight$17
Aug-26-22ReiteratedMorgan StanleyEqual Weight$21
Jul-25-22DowngradeBarclaysEqual WeightUnderweight
Jan-10-22UpgradeBarclaysUnderweightEqual Weight
Latest News· Times ET
Sep-16-26
Sep-14-26
Sep-11-26
Sep-09-26
Sep-04-26
Sep-02-26
Aug-31-26
Aug-30-26
Aug-28-26
Aug-28-2609:02PM
Aug-27-26
Aug-26-26
Company

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
6/30/2026
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue1,5191,5181,296
Cost of Goods Sold Incl. D&A1,0051,006896
Gross Profit512512400
Selling, General and Administrative Excl. Other312313289
Research and Development
000
Other Operating Expense
000
Operating Income198198110
Interest Expense474833
Unusual Expense
Non-Operating Income (Expense)-14-13-9
Net Income Before Taxes13613768
Income Taxes383820
Consolidated Net Income10010048
Net Income From Continuing Operations10010048
Net Income10010048
EPS (Recurring)2.462.461.19
EPS (Basic, Before Extraordinaries)2.462.461.19
EPS (Diluted)2.442.441.19
EBITDA237236147
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio14.1212.8721.46
Price To Sales Ratio0.930.850.81
Gross Margin33.7133.7330.86
Operating Margin13.0313.048.49
Net Margin6.586.593.70
Shares Outstanding414141
Market Capitalization1,4121,2871,047
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$64.60$53.72$42.84$31.97$21.09 Close Price0.00M3.05M6.10M9.14M12.19MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CORCORAN E THOMASDirectorMay 29 '26Buy31.7710,000317,70041,459Jun 02
BENDHEIM JACKPresident and CEOMay 07 '26Sale48.494,528219,56856,152May 07
BENDHEIM JACKPresident and CEOMay 06 '26Sale57.377,040403,85060,680May 07
BENDHEIM JACKPresident and CEOMay 05 '26Sale55.807,040392,81067,720May 07
BENDHEIM JACKPresident and CEOApr 30 '26Sale52.767,040371,46674,760Apr 30
BENDHEIM JACKPresident and CEOApr 29 '26Sale52.927,040372,55281,800Apr 30
BENDHEIM JACKPresident and CEOApr 28 '26Sale55.917,040393,57688,840Apr 30
BENDHEIM JACKPresident and CEOApr 23 '26Sale54.097,040380,82695,880Apr 23
BENDHEIM JACKPresident and CEOApr 22 '26Sale54.297,040382,185102,920Apr 23
BENDHEIM JACKPresident and CEOApr 21 '26Sale55.987,040394,081109,960Apr 23
BENDHEIM JACKPresident and CEOApr 16 '26Sale54.647,040384,661117,000Apr 16
BENDHEIM JACKPresident and CEOApr 15 '26Sale56.967,040401,01124,040Apr 16
BENDHEIM JACKPresident and CEOApr 14 '26Sale59.087,040415,92231,080Apr 16
BENDHEIM JACKPresident and CEOMar 31 '26Sale53.907,040379,42838,120Mar 31
BENDHEIM JACKPresident and CEOMar 30 '26Sale53.617,040377,40645,160Mar 31
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.